



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/825,866

04/16/2004

Michael A. Spohn

CV/04-001

8191

21140 7590 12/29/2006  
GREGORY L BRADLEY  
MEDRAD INC  
ONE MEDRAD DRIVE  
INDIANOLA, PA 15051

EXAMINER

MACNEILL, ELIZABETH

ART UNIT

PAPER NUMBER

3767

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

12/29/2006

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

## Office Action Summary

Application No.

10/825,866

Applicant(s)

SPOHN ET AL.

Examiner

Elizabeth R. MacNeill

Art Unit

3767

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 10 November 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-82 is/are pending in the application.
- 4a) Of the above claim(s) 17-25 and 50-82 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-16 and 26-49 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 16 April 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 11/9/2006.
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- ☐ Notice of Informal Patent Application
- ☐ Other: \_\_\_\_\_.

**DETAILED ACTION**

***Election/Restrictions***

1. Applicant's election of Group I and Species IV in the reply filed on 10 November 2006 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claims 1-16 and 26-49 are readable on the elected invention and species.

***Claim Rejections - 35 USC § 102***

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 1-6, 8-10, 12-16, 26-30, 36-40 and 42 are rejected under 35 U.S.C. 102(b) as being anticipated by Schwietzer, Jr et al (US 5,584,671).

Regarding claims 1 and 26, Schweitzer Jr et al teaches an injector system comprising; a source of injection fluid; a pump device (16); a fluid path set (20,21) disposed between the source of injection fluid and the pump device, and comprising a multi-position valve (19); a fluid control device (26) operatively associated with the fluid path set and comprising a valve actuator (14) adapted to operate the multi-position valve, the valve actuator adapted to close the multi-position valve to isolate the pump device from a patient and stop flow of the injection fluid to the patient at substantially any

pressure or flow rate generated by the pump device for delivering a sharp bolus of the injection fluid to the patient.

Regarding claim 2, the valve actuator is further adapted to selectively place the pump device in fluid communication with the source of injection fluid for supplying the injection fluid to the pump device.

Regarding claims 3 and 27, the valve actuator comprises a position indicator (knob) indicating a position of the multi-position valve.

Regarding claims 4 and 28 the valve actuator comprises a sensor (42) indicating presence of the multi-position valve in the valve actuator.

Regarding claims 5 and 29 the valve actuator comprises a retainer (45) for removably supporting the multi-position valve.

Regarding claims 6,10,30 and 40 the fluid path set comprises a drip chamber (23) and the fluid control device comprises a fluid level sensing mechanism (drip sensors, not shown) operatively associated with the drip chamber for sensing the injection fluid level in the drip chamber.

Regarding claim 8, the pump device comprises a powered injector (via 25).

Regarding claim 9, the device further comprises a source of medical fluid (11) associated with the fluid path set; and a pump (16) operatively associated with the source of medical fluid for supplying the medical fluid to the patient via the fluid path set.

Regarding claims 12 and 37 the device further comprises a shut-off valve (19) associated with the pump for stopping flow of the medical fluid to the patient.

Regarding claims 13 and 38 the shut-off comprises an automated pinch valve.

Regarding claims 14,36 and 39 the pump comprises a peristaltic pump (16).

Regarding claims 15 and 42 device further comprises guides (Fig 1) for securing the fluid path set in association with the pump.

Regarding claim 16, the device further comprises a hand held control device (26) for controlling the flow rate of the injection fluid from the pump device.

***Claim Rejections - 35 USC § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 7,11,41, and 43-49 rejected under 35 U.S.C. 103(a) as being unpatentable over Schweitzer Jr et al in view of Duchon et al (US 6,099,502). Schweitzer Jr et al teaches the limitations of claims 1 and 26 as above, but fails to teach the inclusion of an air detector assembly. Duchon et al teaches a powered infusion device with an air column detector (552) disposed along a fluid path (588) with a retaining device (627,628), and a base (540) (Fig 19). To use a clear plastic would have been a matter of obvious design choice.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to include the air in line detector and retaining member set of Duchon with

Art Unit: 3767

the injector of Schweitzer Jr in order to prevent the injection of air bubbles into the patient.

6. Claims 31-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schweitzer Jr et al as applied to claims 1 and 26 above, and further in view of Sunderland (US 5,057,081).

Schweitzer Jr et al teaches the limitations of claims 1 and 26, but does not teach the particulars of the drip chamber. Sunderland teaches a drip chamber for use in a peristaltic infusion device wherein the drip chamber (42) includes a body (48) with a longitudinally extending projection (37), an optical fluid level sensor (43), and a drip chamber support (39). The use of two drip chambers would be an obvious duplication of parts (*St Regis Paper Co v. Bemis Co.*, 193 USPQ 8). It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the drip chamber and support of Sunderland in order to securely lock the drip chamber to the pump housing and ensure the drip chamber is in communication with the optical sensors.

### **Conclusion**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth R. MacNeill whose telephone number is (571)-272-9970. The examiner can normally be reached on 7:00-3:30pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571)272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3767

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ERM

*Elyett Maclell*  
*12/20/06*

KEVIN C. SIRMONS  
SUPERVISORY PATENT EXAMINER

*Kevin C. Sirmors*